SCHEMBL22357985

SCHEMBL22357985

CC(C)n1ncc2ccc(-c3noc(C4CCN(C(=O)CNC(=O)OC(C)(C)C)CC4)n3)cc21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMO Q99835 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.41
GAA P10253 1/20 0.41
HTT P42858 1/20 0.41
LMNA P02545 2/20 0.41
TSHR P16473 2/20 0.41
TUBB4A P04350 1/20 0.41
TUBB P07437 1/20 0.41
TUBA3C P0DPH7 1/20 0.41
TUBA1B P68363 1/20 0.41
TUBA4A P68366 1/20 0.41
TUBB4B P68371 1/20 0.41
TUBB3 Q13509 1/20 0.41
TUBB2A Q13885 1/20 0.41
TUBB8 Q3ZCM7 1/20 0.41
TUBA3E Q6PEY2 1/20 0.41
TUBA1A Q71U36 1/20 0.41
TUBA1C Q9BQE3 1/20 0.41
TUBB6 Q9BUF5 1/20 0.41
TUBB2B Q9BVA1 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20116363 0.88 SMO (0.37) SMOSMN1; SMN2GAAHTTTSHR
SCHEMBL22358127 0.87 GPR119 (0.47) SMOSMN1; SMN2HTTLMNATSHR
SCHEMBL22357783 0.86 TUBB4A (0.47) SMOSMN1; SMN2GAAHTTLMNA
SCHEMBL22358188 0.86 SMN1; SMN2 (0.46) SMOSMN1; SMN2LMNATSHRALOX15
SCHEMBL22357886 0.84 GPR119 (0.44) SMOSMN1; SMN2HTTLMNATSHR
SCHEMBL22358218 0.84 GPR119 (0.44) SMOSMN1; SMN2HTTLMNATSHR
SCHEMBL20116437 0.84 KIT (0.47) SMOSMN1; SMN2LMNATSHR
SCHEMBL22358020 0.84 GPR119 (0.44) SMOSMN1; SMN2HTTLMNATSHR
SCHEMBL22358214 0.84 KIT (0.47) SMOSMN1; SMN2LMNATSHR
SCHEMBL22357937 0.84 LMNA (0.47) SMOSMN1; SMN2LMNATSHRALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 US disclosed
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 US disclosed
US-20200262828-A1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2020-08-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11873298-B2 Compounds and uses thereof NLN, ACHE, CLN6 SMO 1858/4885SMN1; SMN2 13/4885GAA 67/4885
US-20200262828-A1 COMPOUNDS AND USES THEREOF NLN, ACHE, CLN6 SMO 1858/4885SMN1; SMN2 13/4885GAA 67/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.